News About: Pharm. Industry
‘The pharmaceutical industry is looking to occupy the KRW 15 billion neutropenia treatment market’
The neutropenia treatment market, expected to form a KRW 15 billion market for the first time and grow significantly every year, will get into a competing structure.
It is known that the top pharmaceutical companies ...
Having the hostile M&A controversy, Ildong Pharmaceutical will pay KRW 1.47 billion cash dividends to Green Cross
While a part of the pharmaceutical industry expects that Green Cross will try a hostile M&A on Ildong Pharmaceutical, Green Cross will receive KRW 1.471 billion cash dividends through distribution of the Ildong Pharma...
Damages of the price-fixing case of ‘Zofran’ and ‘Ondaron’ has been recomputed to KRW 1.2 billion
The National Health Insurance Service (NHIS) raised damages for the reverse payment lawsuit case between GSK and Dong-A ST from KRW 470 million to KRW 1.2 billion.
At first, based on the economic analysis data of the...
In 2015, multinational pharmaceutical companies have shown competition in the asthma and COPD treatments
Since the beginning of the New Year, multinational pharmaceutical companies have shown high interests in asthma and COPD (Chronic Obstructive Pulmonary Disease) treatments.
As the number of asthma and chronic obstruc...
Exports in pharmaceutical products were $4.57 billion, a 20.3% increase, last year
It is known that exports of pharmaceutical products in 2014were increased by 20.3% with $4.57 billion compared to the year of 2013 with $3.8 billion.
On the other hand, imports of pharmaceutical products in the last ...
CEO Han-gi Kim was appointed as the new president of the Korea Pharmaceutical Traders Association
CEO Han-gi Kim of Sinsin Pharm was appointed as the new president of the Korea Pharmaceutical Traders Association (KPTA).
The KPTA held the 57th general meeting at the Palace Hotel Seoul on 27thand unanimously select...
Dong-A Socio Holdings will be divided into investment business and biosimilar business
Dong-A Socio Holdings will be divided into investment business and biosimilar business.
With the object of establishing a management structure, dispersing management dangers, raising company and shareholder values, t...
What are reasons for pharmaceutical companies to replace their MRs to CSOs?
It is observed that some mid-sized pharmaceutical companies are working on transferring medical representatives (MR) to contract sales organizations (CSO).
According to the pharmaceutical industry, several mid-sized ...
Ildong Pharmaceutical will be inevitable to have a voting challenge against Green Cross on the general meeting of shareholdersTriggered by the shareholder proposal of the 2nd largest shareholder of Ildong Pharmaceutical, Green Cross, the M&A conflict between the two companies will lead to voting.
Ildo...
|
Pharmaceutical companies having more than KRW 300 billion sales recorded only 6.3% in the rate of business profits
Profitability of the top sale pharmaceutical companies has been weakening.
According to the YakupDotCom’s analysis result of business performances of pharmaceutical companies having more than KRW 300 billion sales, t...
